News | Cath Lab | March 01, 2023

SpectraWAVE Secures 510(k) Clearance of HyperVue Intravascular Imaging System

System Leverages Next Generation DeepOCTÔ Technology and Near Infrared Spectroscopy to Optimize Coronary Stent Placement in the Cardiac Catheterization Lab

System Leverages Next Generation DeepOCTÔ Technology and Near Infrared Spectroscopy to Optimize Coronary Stent Placement in the Cardiac Catheterization Lab

March 1, 2023 — SpectraWAVE, Inc., a medical imaging company focused on improving the treatment and outcomes for patients with coronary artery disease (CAD), today announced Food and Drug Administration (FDA) 510(k) clearance of their flagship intravascular imaging system, HyperVue. The system combines next-generation DeepOCT images and near infrared spectroscopy (NIRS) with state-of-the-art ease of use to support physicians optimizing coronary stenting in the cardiac catheterization lab. In addition, the system has now been used by multiple physicians as part of a first-in-human study.

“This is a landmark day for SpectraWAVE, but more importantly, a critical step towards improving outcomes for patients with coronary artery disease,” said Eman Namati, Ph.D., Chief Executive Officer of SpectraWAVE. “Our proprietary DeepOCT-NIRS imaging system pushes the technological limits of optical coherence tomography—both in image quality and depth—while combining it with spectroscopy for the first time, packaging both into a no-flush catheter with an artificial intelligence-powered user experience. With this regulatory clearance, we are excited to begin the transition to a commercial entity and launch our product.”

“Clinical evidence strongly suggests that patients benefit from intravascular imaging-guided stent optimization,” said Ziad A. Ali, M.D., D.Phil, Director of the DeMatteis Cardiovascular Institute at St. Francis Hospital and Heart Center and Director of the Angiographic Core Laboratory at the Cardiovascular Research Foundation in New York. “After completing the first-in-human procedures, it’s clear SpectraWAVE has built something truly special with a combination of DeepOCT and NIRS, paired with a workflow and AI-enabled image analysis that will prove beneficial for precise and optimal CAD treatment. The DeepOCT technology provides exceptional visualization of critical structures such as the external elastic membrane and calcium, while NIRS removes the guesswork in classifying lipidic plaques. I believe the HyperVue system will enable comprehensive and seamless PCI optimization, but also act as a trailblazing tool for future applications in high-risk vulnerable plaque detection and treatment.”

Intravascular imaging has become an essential tool to optimize the approximately 1 million coronary stenting procedures per year in the United States, providing key insights into plaque morphology, plaque modification decisions, stent and balloon sizing and landing zone selection, confirmation of treatment optimization and future adverse event risk. The HyperVue system is the first to combine two critically important imaging technologies, DeepOCT and NIRS, while optimizing for image quality and procedural efficiency in the cath lab. The Starlight Imaging Catheter delivers rapid pullbacks of both imaging modalities in a single, low-profile, no-flush form factor. The physician controls both image acquisition and artificial intelligence-enabled image review from the sterile field, a workflow designed for simplicity when optimizing percutaneous coronary intervention (PCI).  

Initial cases from the first-in-human study (NCT05241665) have been conducted at the Department of Research Innovation, Angiografia de Occidente in Colombia, South America under the guidance of site Principal Investigators Antonio Dager, M.D., Interventional Cardiologist and Director of the Structural Heart Program, as well as study Principal Investigator Dr. Ali.

For more information: www.spectrawave.com


Related Content

News | Cath Lab

September 13, 2023 — A diagnostic test, first offered in the United States at University Hospitals (UH) Harrington Heart ...

Home September 13, 2023
Home
News | Cath Lab

August 2, 2023 — Teleflex Incorporated, a leading global provider of medical technologies, announced the U.S Food and ...

Home August 02, 2023
Home
News | Cath Lab

July 13, 2023 — Mount Sinai Queens announced the opening of a new cardiac catheterization lab that will provide rapid ...

Home July 13, 2023
Home
News | Cath Lab

June 21, 2023 — Royal Philips, a global leader in health technology, announced it has teamed up with BIOTRONIK (Lake ...

Home June 21, 2023
Home
News | Cath Lab

May 16, 2023 — Royal Philips, a global leader in health technology, announced late-breaking data from the DCR4Contrast ...

Home May 16, 2023
Home
News | Cath Lab

March 14, 2023 — Royal Philips, a global leader in health technology, and the Gibraltar Health Authority, announced they ...

Home March 14, 2023
Home
News | Cath Lab

May 31, 2022 — Innovative Health, LLC, a specialty cardiology reprocessor, announced that the company has received ...

Home May 31, 2022
Home
News | Cath Lab

May 26, 2022 — The U.S. Food and Drug Administration (FDA) has recalled the Dragonfly OpStar Imaging Catheter, and has ...

Home May 26, 2022
Home
News | Cath Lab
April 25, 2022 – NewYork-Presbyterian Hudson Valley Hospital celebrated the launch of its interventional cardiology ...
Home April 25, 2022
Home
News | Cath Lab
April 18, 2022 – Royal Philips and Oulu University Hospital (Finland) have announced a strategic 10-year partnership ...
Home April 18, 2022
Home
Subscribe Now